Circumvent Pharmaceuticals

Circumvent Pharmaceuticals was formed to address the growing global burden of neurodegenerative disease by developing targeted treatments based on novel biological insights. The company's initial focus is on CLN1 Batten Disease, a rare and fatal childhood disorder, where they are investigating therapeutic strategies to modulate the palmitoylome—a network of proteins modified by palmitate. Through this work, they have gained unique understanding of synaptic architecture and function, which they are applying to a broader pipeline of rare and common neurological conditions. Their strategy prioritizes diseases with predictive models and efficient paths to market.

A platform focused on modulating the palmitoylome—the network of proteins modified by palmitate—to correct synaptic dysfunction and address the root cause of certain neurodegenerative diseases like CLN1 Batten Disease.

Total raised: $60M

Direct competition in CLN1 Batten Disease is limited due to the absence of approved therapies. Circumvent's main differentiation is its deep, platform-based focus on the palmitoylome as a root cause mechanism, rather than just enzyme replacement. Potential future competitors include gene therapy companies and other biotefts targeting related pathways in neurodegeneration.